| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | VGLUT3, VGluT3, VGLU3, SLC17A8, Solute Carrier Family 17 Member 8, Solute Carrier Family 17 (Sodium-Dependent Inorganic Phosphate Cotransporter) Member 8, Solute Carrier Family 17 (Vesicular Glutamate Transporter) Member 8, Vesicular Glutamate Transporter 3, DFNA25, Deafness Autosomal Dominant 25 |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | Fusion protein amino acids 546-588 (cytoplasmic C-terminus) of rat VGLUT3 |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
Vesicular Glutamate Transporter 3 (VGLUT3) is a specialized multipass membrane protein localized to synaptic vesicles, where it facilitates the uptake of glutamate—a critical excitatory neurotransmitter—into vesicles for synaptic release. Unlike other VGLUT isoforms, VGLUT3 exhibits a unique and restricted expression pattern, predominantly found in the amygdala, cerebellum, hippocampus, medulla, spinal cord, and thalamus. These brain regions are central to emotion regulation, motor coordination, memory, and sensory processing, all of which are commonly affected in neurodegenerative disorders.
VGLUT3 shares approximately 72% sequence homology with VGLUT2 and BNPI, suggesting evolutionary conservation and potential functional overlap, yet it also displays distinct physiological roles. Emerging research implicates VGLUT3 in the pathophysiology of several neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, and epilepsy, due to its involvement in non-canonical glutamatergic signaling and neuromodulation.
Understanding VGLUT3’s molecular mechanisms and regional specificity is critical for advancing targeted therapies and biomarker development in neurodegenerative disease research. As a modulator of both excitatory and inhibitory circuits, VGLUT3 represents a promising focal point for neuroscience investigations into synaptic plasticity, neurotransmitter co-release, and circuit dysfunction.
1 µg/ml of SMC-397 was sufficient for detection of VGLUT3 in 20 µg of CV-1 fibroblast cells (lysate) transfected with VGLUT3 by colorimetric immunoblot analysis using goat anti-mouse IgG:HRP as the secondary antibody.
Cite this product varies by variant:
- SMC-397D — Size: 100 ug: VGLUT3 Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-397D, RRID: AB_11229704)
- SMC-397D-A390 — Size: 100 ug: VGLUT3 Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-397D-A390, RRID: AB_2700907)
- SMC-397D-A488 — Size: 100 ug: VGLUT3 Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-397D-A488, RRID: AB_2700908)
- SMC-397D-A594 — Size: 100 ug: VGLUT3 Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-397D-A594, RRID: AB_2700910)
- SMC-397D-APC — Size: 100 ug: VGLUT3 Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-397D-APC, RRID: AB_2700916)
- SMC-397D-BI — Size: 100 ug: VGLUT3 Antibody: Biotin (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-397D-BI, RRID: AB_2700917)
- SMC-397D-FITC — Size: 100 ug: VGLUT3 Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-397D-FITC, RRID: AB_2700918)
- SMC-397D-HRP — Size: 100 ug: VGLUT3 Antibody: HRP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-397D-HRP, RRID: AB_2700919)
- SMC-397D-PCP — Size: 100 ug: VGLUT3 Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-397D-PCP, RRID: AB_2700921)
- SMC-397D-RPE — Size: 100 ug: VGLUT3 Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-397D-RPE, RRID: AB_2700922)
- SMC-397S — Size: 12 ug: VGLUT3 Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-397S, RRID: AB_11229704)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
2. Herzog E., et al. (2004) Neurosci. 123(4): 983-1002.